These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 6192185)
21. Relative antiviral activity of in vitro-synthesized murine interferon-alpha 4 and -alpha 1. Beilharz MW; Swaminathan N; Lai CM; Pitha PM; Boyer SJ J Interferon Res; 1991 Feb; 11(1):9-15. PubMed ID: 1851507 [TBL] [Abstract][Full Text] [Related]
22. Production and characterization of anti-murine interferon-gamma sera. Havell EA; Spitalny GL J Interferon Res; 1983; 3(2):191-8. PubMed ID: 6409971 [TBL] [Abstract][Full Text] [Related]
23. Macrophage colony stimulating factor (CSF-1) blocks the myeloid suppressive but not the antiviral or antiproliferative activities of murine alpha, beta, and gamma interferons in vitro. Koren S; Klimpel GR; Fleischmann WR J Biol Response Mod; 1986 Dec; 5(6):571-80. PubMed ID: 2432191 [TBL] [Abstract][Full Text] [Related]
24. Antiviral and antiproliferative properties of liposome-associated human interferon-gamma. Smith DM; Mayhew E; Reszka R; Ito M; O'Malley JA J Interferon Res; 1990 Apr; 10(2):153-60. PubMed ID: 2111353 [TBL] [Abstract][Full Text] [Related]
25. Chemical modification of mouse interferons. Rusckowski M; Paucker M; Dalton B; Ogburn CA J Interferon Res; 1982; 2(2):177-85. PubMed ID: 6181175 [TBL] [Abstract][Full Text] [Related]
26. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022 [TBL] [Abstract][Full Text] [Related]
27. Regulation of MuIFN-alpha/beta and MuIFN-gamma-induced antiviral states: differential effects with different challenge viruses and lack of correlation with 2'5' oligoadenylate synthetase levels. Ramamurthy V; Fleischmann WR J Biol Regul Homeost Agents; 1988; 2(1):7-14. PubMed ID: 2845725 [TBL] [Abstract][Full Text] [Related]
28. Characterization of antiviral activity of spotted souslik (Spermophilus suslicus) interferons. Kandefer-Szerszeń M Arch Immunol Ther Exp (Warsz); 1987; 35(4):489-99. PubMed ID: 2449874 [TBL] [Abstract][Full Text] [Related]
29. Quantitation of in vivo potentiation resulting from combined interferon therapy: antitumor effect against B-16 melanoma in mice. Koren S; Fleischmann WR J Interferon Res; 1986 Oct; 6(5):473-82. PubMed ID: 2433361 [TBL] [Abstract][Full Text] [Related]
31. Treatment of mice with macrophage colony stimulating factor (CSF-1) prevents the in vivo myelosuppression induced by murine alpha, beta, and gamma interferons. Koren S; Klimpel GR; Fleischmann WR J Biol Response Mod; 1986 Oct; 5(5):481-9. PubMed ID: 3095498 [TBL] [Abstract][Full Text] [Related]
32. Binding and capture of human interferon-alpha by reverse evaporation vesicles, multilamellar vesicles, and small unilamellar vesicles. Eppstein DA; Stewart WE J Interferon Res; 1981; 1(4):495-504. PubMed ID: 6180083 [TBL] [Abstract][Full Text] [Related]
33. Interferon entry through the blood-brain barrier in glioma and its effect on lipoxygenase activity. Wiranowska M; Prockop LD; Naidu AK; Saporta S; Kori S; Kulkarni AP Anticancer Res; 1994; 14(3A):1121-6. PubMed ID: 7521151 [TBL] [Abstract][Full Text] [Related]